All In Biotech

Drug Trial Radar · NCT07487896

A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

A Randomized, Controlled, Multicenter Phase III Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy (TAISHAN-303)

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

440

Planned (sponsor's estimate)

Start

Mar 24, 2026

Primary completion

Apr 30, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a large clinical study carried out at multiple hospitals. Participants will be randomly assigned to one of two groups: one group will receive a new medicine called YL201, and the other group will receive standard chemotherapy chosen by the doctor. The purpose of the study is to see whether YL201 works better and is safer for people with locally advanced or metastatic esophageal squamous cell carcinoma whose first-line treatment has stopped working. The study will also look at how YL201 is processed in the body (Pharmacokinetics), whether it triggers any immune reactions, and whether certain biological markers can help predict how well it works.

Conditions

  • Advanced Esophageal Squamous Cell Carcinoma

Interventions

  • YL201Drug

    YL201, a B7H3 targeting ADC,administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).

  • PaclitaxelDrug

    175 mg/m², administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).

  • DocetaxelDrug

    75 mg/m², administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).

  • IrinotecanDrug

    125 mg/m², administered on Days 1 and 8 of each cycle, intravenous infusion, every 3 weeks (Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to Approximately 36 Months

Locations

81 sites in 1 country. Site status is shown where the registry gives one.

  • 144

    Anqing, Anhui, China · Recruiting

  • 135

    Bengbu, Anhui, China · Recruiting

  • 133

    Hefei, Anhui, China · Recruiting

  • 143

    Hefei, Anhui, China · Recruiting

  • 129

    Beijing, Beijing Municipality, China · Recruiting

  • 161

    Beijing, Beijing Municipality, China · Recruiting

  • 183

    Beijing, Beijing Municipality, China · Recruiting

  • 119

    Chongqing, Chongqing Municipality, China · Recruiting

  • 120

    Chongqing, Chongqing Municipality, China · Recruiting

  • 110

    Fuzhou, Fujian, China · Not yet recruiting

  • 147

    Fuzhou, Fujian, China · Recruiting

  • 145

    Xiamen, Fujian, China · Recruiting

  • 175

    Lanzhou, Gansu, China · Recruiting

  • 149

    Guangzhou, Guangdong, China · Recruiting

  • 154

    Guangzhou, Guangdong, China · Recruiting

  • 112

    Nanning, Guangxi, China · Recruiting

  • 150

    Nanning, Guangxi, China · Recruiting

  • 184

    Foshan, Guangzhou, China · Recruiting

  • 168

    Meizhou, Guangzhou, China · Recruiting

  • 169

    Shantou, Guangzhou, China · Recruiting

  • 158

    Handan, Hebei, China · Recruiting

  • 176

    Handan, Hebei, China · Recruiting

  • 180

    Langfang, Hebei, China · Recruiting

  • 156

    Shijiazhuang, Hebei, China · Recruiting

  • 159

    Shijiazhuang, Hebei, China · Recruiting

  • 122

    Harbin, Heilongjiang, China · Recruiting

  • 170

    Harbin, Heilongjiang, China · Recruiting

  • 102

    Anyang, Henan, China · Recruiting

  • 105

    Luoyang, Henan, China · Recruiting

  • 132

    Nanyang, Henan, China · Recruiting

  • 103

    Zhengzhou, Henan, China · Recruiting

  • 104

    Zhengzhou, Henan, China · Recruiting

  • 142

    Zhengzhou, Henan, China · Recruiting

  • 113

    Wuhan, Hubei, China · Recruiting

  • 114

    Wuhan, Hubei, China · Recruiting

  • 148

    Wuhan, Hubei, China · Recruiting

  • 155

    Yichang, Hubei, China · Recruiting

  • 151

    Changsha, Hunan, China · Recruiting

  • 182

    Changsha, Hunan, China · Recruiting

  • 165

    Huai'an, Jiangsu, China · Recruiting

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.